St John's wort greatly reduces the concentrations of oral oxycodone

European Journal of Pain

Volumn 14, Issue 8, 2010, Pages 854-859

  Nieminen, Tuija H ^a   Hagelberg, Nora M ^a   Saari, Teijo I ^a   Neuvonen, Mikko ^b   Laine, Kari ^c   Neuvonen, Pertti J ^b   Olkkola, Klaus T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Hypericum perforatum; Interaction; Oxycodone; Pharmacokinetics; St John's wort

Indexed keywords

HYPERICUM PERFORATUM EXTRACT; MORPHINE DERIVATIVE; NOROXYCODONE; NOROXYMORPHONE; OXYCODONE; OXYMORPHONE; PLACEBO; TROPISETRON; UNCLASSIFIED DRUG;

ADULT; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COLD PRESSOR TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEADACHE; HUMAN; HYPERICUM PERFORATUM; MALE; NAUSEA; PAIN THRESHOLD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; VISUAL ANALOG SCALE; VOMITING;

ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; MALE; OXYCODONE; PAIN THRESHOLD; PLANT EXTRACTS;

EID: 77956057096     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2009.12.007     Document Type: Article

References (53)

1. M.P. Adams, and H. Ahdieh Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets Drugs 6 2005 91 99
2. M.J. Bair, R.L. Robinson, W. Katon, and K. Kroenke Depression and pain comorbidity: a literature review Arch Intern Med 163 2003 2433 2445
3. S. Bauer, E. Stormer, A. Johne, H. Kruger, K. Budde, and H.H. Neumayer Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients Brit J Clin Pharmacol 55 2003 203 211
4. A. Bond, and M. Lader The use of analogue scales in rating subjective feelings Brit J Med Psychol 47 1974 211 218
5. H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment Eur J Pain 10 2006 287 333
6. D.G. Cogan Simplified entoptic pupillometer Am J Ophthalmol 24 1941 1431 1433
7. G.K. Dresser, U.I. Schwarz, G.R. Wilkinson, and R.B. Kim Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects Clin Pharmacol Ther 73 2003 41 50
8. D. Dürr, B. Stieger, G.A. Kullak-Ublick, K.M. Rentsch, H.C. Steinert, and P.J. Meier St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 Clin Pharmacol Ther 68 2000 598 604
9. D. Eich-Höchli, R. Oppliger, K.P. Golay, P. Baumann, and C.B. Eap Methadone maintenance treatment and St. John's wort - a case report Pharmacopsychiatry 36 2003 35 37
10. J. Gimbel, and H. Ahdieh The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain Anesth Analg 99 2004 1472 1477
11. U. Gödtel-Armbrust, A. Metzger, U. Kroll, O. Kelber, and L. Wojnowski Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort Naunyn Schmiedebergs Arch Pharmacol 375 2007 377 382
12. J.M. Greeson, B. Sanford, and D.A. Monti St John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature Psychopharmacology 153 2001 402 414
13. O. Gureje, M. Von Korff, G.E. Simon, and R. Gater Persistent pain and well-being: a World Health Organization Study in Primary Care JAMA 280 1998 147 151
14. M.E. Hale, C. Dvergsten, and J. Gimbel Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study J Pain 6 2005 21 28
15. K. Hamunen, P. Paakkari, and E. Kalso Trends in opioid consumption in the Nordic countries 2002-2006 Eur J Pain 13 2009 954 962
16. J.G. Hannington-Kiff Measurement of recovery from outpatient general anaesthesia with a simple ocular test Brit Med J 3 1970 132 135
17. T. Heiskanen, K.T. Olkkola, and E. Kalso Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone Clin Pharmacol Ther 64 1998 603 611
18. M. Hennessy, D. Kelleher, J.P. Spiers, M. Barry, P. Kavanagh, and D. Back St Johns wort increases expression of P-glycoprotein: implications for drug interactions Brit J Clin Pharmacol 53 2002 75 82
19. H. Imai, T. Kotegawa, K. Tsutsumi, T. Morimoto, N. Eshima, and S. Nakano The recovery time-course of CYP3A after induction by St John's wort administration Brit J Clin Pharmacol 65 2008 701 707
20. A. Johne, J. Brockmöller, S. Bauer, A. Maurer, M. Langheinrich, and I. Roots Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) Clin Pharmacol Ther 66 1999 338 345
21. S.F. Jones, H.J. McQuay, R.A. Moore, and C.W. Hand Morphine and ibuprofen compared using the cold pressor test Pain 34 1988 117 122
22. R.F. Kaiko Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone Clin Pharmacol Ther 59 1996 52 61
23. R.C. Kessler, J. Soukup, R.B. Davis, D.F. Foster, S.A. Wilkey, and M.I. Van Rompay The use of complementary and alternative therapies to treat anxiety and depression in the United States Am J Psychiatry 158 2001 289 294
24. E.D. Kharasch, C. Hoffer, D. Whittington, and P. Sheffels Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine Clin Pharmacol Ther 74 2003 543 554
25. E.D. Kharasch, C. Hoffer, and D. Whittington The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone Brit J Clin Pharmacol 57 2004 600 610
26. B. Lalovic, B. Phillips, L.L. Risler, W. Howald, and D.D. Shen Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes Drug Metab Dispos 32 2004 447 454
27. B. Lalovic, E. Kharasch, C. Hoffer, L. Risler, L.Y. Liu-Chen, and D.D. Shen Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites Clin Pharmacol Ther 79 2006 461 479
28. K.K. Lemberg, T. Heiskanen, V.K. Kontinen, and E.A. Kalso Pharmacology of oxycodone: does it explain why oxycodone has become a bestselling strong opioid? Scand J Pain 1 2009 S18 S23
29. K. Linde, M.M. Berner, and L. Kriston St John's wort for major depression Cochrane Database Syst Rev 4 2008 CD000448
30. R. Madabushi, B. Frank, B. Drewelow, H. Derendorf, and V. Butterweck Hyperforin in St. John's wort drug interactions Eur J Clin Pharmacol 62 2006 225 233
31. I. Mai, S. Bauer, E.S. Perloff, A. Johne, B. Uehleke, and B. Frank Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction Clin Pharmacol Ther 76 2004 330 340
32. P.T. Mäntyselkä, J.H. Turunen, R.S. Ahonen, and E.A. Kumpusalo Chronic pain and poor self-rated health JAMA 290 2003 2435 2442
33. J.S. Markowitz, J.L. Donovan, C.L. DeVane, R.M. Taylor, Y. Ruan, and J.S. Wang Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme JAMA 290 2003 1500 1504
34. J. Marsh, C. Hager, T. Havey, S. Sprague, M. Bhandari, and D. Bryant Use of alternative medicines by patients with OA that adversely interact with commonly prescribed medications Clin Orthop Relat Res 467 2009 2705 2722
35. E. Michna, E.L. Ross, W.L. Hynes, S.S. Nedeljkovic, S. Soumekh, and D. Janfaza Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history J Pain Symptom Manage 28 2004 250 258
36. L.B. Moore, B. Goodwin, S.A. Jones, G.B. Wisely, C.J. Serabjit-Singh, and T.M. Willson St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor Proc Natl Acad Sci USA 97 2000 7500 7502
37. S.C. Mueller, J. Majcher-Peszynska, B. Uehleke, S. Klammt, R.G. Mundkowski, and W. Miekisch The extent of induction of CYP3A by St John's wort varies among products and is linked to hyperforin dose Eur J Clin Pharmacol 62 2006 29 36
38. S.C. Mueller, J. Majcher-Peszynska, R.G. Mundkowski, B. Uehleke, S. Klammt, and H. Sievers No clinically relevant CYP3A induction after St John's wort with low hyperforin content in healthy volunteers Eur J Clin Pharmacol 65 2009 81 87
39. M. Neuvonen, and P.J. Neuvonen Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography- electrospray-tandem mass spectrometry Ther Drug Monit 30 2008 333 340
40. T.H. Nieminen, N.M. Hagelberg, T.I. Saari, A. Pertovaara, M. Neuvonen, and K. Laine Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone Anesthesiology 110 2009 1371 1378
41. A. Portolés, A. Terleira, A. Calvo, I. Martinez, and G. Resplandy Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial J Clin Pharmacol 46 2006 1188 1194
42. R. Pöyhiä, T. Seppälä, K.T. Olkkola, and E. Kalso The pharmacokinetics of oxycodone after intravenous injection in adults Brit J Clin Pharmacol 32 1991 516 518
43. R. Pöyhiä, T. Seppälä, K.T. Olkkola, and E. Kalso The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects Brit J Clin Pharmacol 33 1992 617 621
44. E. Prommer Oxymorphone: a review Support Care Cancer 14 2006 109 115
45. J. Rengelshausen, M. Banfield, K.D. Riedel, J. Burhenne, J. Weiss, and T. Thomsen Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics Clin Pharmacol Ther 78 2005 25 33
46. J. Sistonen, S. Fuselli, A. Levo, and A. Sajantila CYP2D6 genotyping by a multiplex primer extension reaction Clin Chem 51 2005 1291 1295
47. P. Sloan, N. Slatkin, and H. Ahdieh Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study Support Care Cancer 13 2005 57 65
48. C. Staahl, L.L. Christrup, S.D. Andersen, L. Arendt-Nielsen, and A.M. Drewes A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model Pain 123 2006 28 36
49. B.M. Stone Pencil and paper tests-sensitivity to psychotropic drugs Brit J Clin Pharmacol 18 Suppl. 1 1984 15S 20S
50. K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, and K. Harada Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin Clin Pharmacol Ther 70 2001 518 524
51. C. Wandel, R. Kim, M. Wood, and A. Wood Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein Anesthesiology 96 2002 913 920
52. D.L. Whitten, S.P. Myers, J.A. Hawrelak, and H. Wohlmuth The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials Brit J Clin Pharmacol 62 2006 512 526
53. M. Würglics, K. Westerhoff, A. Kaunzinger, A. Wilke, A. Baumeister, and J. Dressman Comparison of German St John's wort products according to hyperforin and total hypericin content J Am Pharm Assoc 41 2001 560 566